Axatilimab Shakes Up cGVHD Treatment and Looks to Move to …

5 days ago · Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

FAQs about Axatilimab Shakes Up cGVHD Treatment and Looks to Move to … Coupon?

Is axatilimab a first-in-class treatment for cGvHD?

At a plenary session of the 65th ASH Annual Meeting and Exposition, Daniel Wolff, MD, chair of the GVHD Center of the University Hospital in Regensburg, Germany, discussed findings from the phase II AGAVE-201 trial of axatilimab, a first-in-class treatment for cGVHD. 1 ...

Is ablation recommended for premature ventricular complexes?

Premature Ventricular Complexes are the condition where the lower chamber of the heart known as ventricles cause extra beats. It is not a life threatening condition but may make the heart function less effective. Management includes lifestyle changes like reducing stress, avoiding excess caffeine intake. Medications belonging to beta blockers calcium channel blockers category are prescribed. Another mode of treatment for premature Ventricular complex is catheter ablation. In this procedure a catheter is inserted into the heart through a vein and the area causing the extra beat is destroyed or ablated using radiofrequency. ...

Does axatilimab work in chronic graft-versus-host disease (cGvHD)?

SAN DIEGO -- Axatilimab achieved rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (cGVHD), according to the phase II AGAVE-201 trial. ...

Does axatilimab treat refractory cGvHD?

Conclusions: The AGAVE-201 pivotal trial met its primary endpoint for all doses studied. Axatilimabtreatment of refractory cGVHD in heavily pretreated patients resulted in robust clinical activity and durable responses in all 3 dose cohorts, with the highest ORR and least toxicity at the 0.3 mg/kg Q2W dose. ...

How effective is axatilimab?

Dr. Wolff concluded that axatilimab is highly effective with a manageable safety profile. He noted that future studies will illuminate whether the treatment might also be helpful earlier in patients’ treatment course. “Prevention of fibrosis would be better than treating it,” Dr. Wolff said. ...

What is axatilimab?

Axatilimab is an investigational, high-affinity anti-CSF-1R monoclonal antibody that targets monocytes and macrophages, and was shown to have biological and clinical activity in heavily pre-treated patients with cGVHD in a phase I/II study. ...